vs
Side-by-side financial comparison of CARTERS INC (CRI) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $757.8M, roughly 1.4× CARTERS INC). Hologic runs the higher net margin — 17.1% vs 1.5%, a 15.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -0.1%). Hologic produced more free cash flow last quarter ($215.2M vs $-144.1M).
Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
CRI vs HOLX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $757.8M | $1.0B |
| Net Profit | $11.6M | $179.1M |
| Gross Margin | 45.1% | 56.0% |
| Operating Margin | 3.8% | 22.6% |
| Net Margin | 1.5% | 17.1% |
| Revenue YoY | -0.1% | 2.5% |
| Net Profit YoY | -80.1% | -10.9% |
| EPS (diluted) | $0.32 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0B | ||
| Q3 25 | $757.8M | $1.0B | ||
| Q2 25 | $585.3M | $1.0B | ||
| Q1 25 | $629.8M | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $988.0M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $179.1M | ||
| Q3 25 | $11.6M | $187.2M | ||
| Q2 25 | $446.0K | $194.9M | ||
| Q1 25 | $15.5M | $-17.4M | ||
| Q4 24 | — | $201.0M | ||
| Q3 24 | — | $178.6M | ||
| Q2 24 | — | $194.5M | ||
| Q1 24 | — | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | 45.1% | 55.6% | ||
| Q2 25 | 48.1% | 56.3% | ||
| Q1 25 | 46.2% | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | — | 22.6% | ||
| Q3 25 | 3.8% | 22.6% | ||
| Q2 25 | 0.7% | 24.9% | ||
| Q1 25 | 4.1% | -0.7% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 20.7% |
| Q4 25 | — | 17.1% | ||
| Q3 25 | 1.5% | 17.8% | ||
| Q2 25 | 0.1% | 19.0% | ||
| Q1 25 | 2.5% | -1.7% | ||
| Q4 24 | — | 19.7% | ||
| Q3 24 | — | 18.1% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | — | 16.7% |
| Q4 25 | — | $0.79 | ||
| Q3 25 | $0.32 | $0.84 | ||
| Q2 25 | $0.01 | $0.86 | ||
| Q1 25 | $0.43 | $-0.08 | ||
| Q4 24 | — | $0.87 | ||
| Q3 24 | — | $0.75 | ||
| Q2 24 | — | $0.82 | ||
| Q1 24 | — | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.2M | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $864.6M | $5.2B |
| Total Assets | $2.5B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4B | ||
| Q3 25 | $184.2M | $2.2B | ||
| Q2 25 | $338.2M | $1.9B | ||
| Q1 25 | $320.8M | $1.6B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | $5.2B | ||
| Q3 25 | $864.6M | $5.0B | ||
| Q2 25 | $853.9M | $4.8B | ||
| Q1 25 | $847.2M | $4.6B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $5.1B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $4.8B |
| Q4 25 | — | $9.2B | ||
| Q3 25 | $2.5B | $9.0B | ||
| Q2 25 | $2.5B | $8.8B | ||
| Q1 25 | $2.3B | $8.5B | ||
| Q4 24 | — | $8.7B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $8.9B | ||
| Q1 24 | — | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-128.0M | $229.9M |
| Free Cash FlowOCF − Capex | $-144.1M | $215.2M |
| FCF MarginFCF / Revenue | -19.0% | 20.5% |
| Capex IntensityCapex / Revenue | 2.1% | 1.4% |
| Cash ConversionOCF / Net Profit | -11.04× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $229.9M | ||
| Q3 25 | $-128.0M | $355.1M | ||
| Q2 25 | $40.3M | $343.3M | ||
| Q1 25 | $-48.6M | $169.4M | ||
| Q4 24 | — | $189.3M | ||
| Q3 24 | — | $367.0M | ||
| Q2 24 | — | $405.8M | ||
| Q1 24 | — | $292.4M |
| Q4 25 | — | $215.2M | ||
| Q3 25 | $-144.1M | $341.4M | ||
| Q2 25 | $24.1M | $330.5M | ||
| Q1 25 | $-59.0M | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | — | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | -19.0% | 32.5% | ||
| Q2 25 | 4.1% | 32.3% | ||
| Q1 25 | -9.4% | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 2.1% | 1.3% | ||
| Q2 25 | 2.8% | 1.3% | ||
| Q1 25 | 1.6% | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | -11.04× | 1.90× | ||
| Q2 25 | 90.37× | 1.76× | ||
| Q1 25 | -3.13× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRI
| Sales Channel Directly To Consumer | $362.3M | 48% |
| Sales Channel Through Intermediary | $283.8M | 37% |
| Other | $110.4M | 15% |
| Gift Cards | $1.3M | 0% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
